Telemetry Investments, L.L.C. Contrafect Corp Transaction History

Telemetry Investments, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.79 - $4.45 $58,570 - $93,418	-20,993 Reduced 31.34%	46,000 $141,000
Q1 2022 May 16, 2022	SELL	$2.26 - $3.84 $162,753 - $276,537	-72,015 Reduced 51.81%	66,993 $245,000
Q4 2021 Feb 14, 2022	BUY	$2.47 - $4.14 $11,426 - $19,151	4,626 Added 3.44%	139,008 $366,000
Q3 2021 Nov 15, 2021	BUY	$3.19 - $4.43 $9,997 - $13,883	3,134 Added 2.39%	134,382 $544,000
Q2 2021 Aug 16, 2021	BUY	$3.58 - $4.9 $308,767 - $422,615	86,248 Added 191.66%	131,248 $577,000

Q1 2021 May 17, 2021	BUY	$4.46 - $6.68 $200,700 - $300,600	45,000 New	45,000 $216,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Telemetry Investments, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Telemetry Investments, L.L.C. with notifications on news.